TrialNature medicine2022

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.

Irene L M Reijers et al.PubMed ↗Publisher ↗

No numbers read from the abstract.